AoU Research Priorities Use Cases

What is the long-term comparative effectiveness of empagliflozin in a heterogeneous population with type 2 diabetes?

Empaglifozin, a highly selective sodium-glucose cotransport 2 (SGLT2) inhibitor, has been shown to significantly reduce major adverse cardiovascular (CV) events and hospitalization for heart failure in patients with type 2 diabetes (T2DM) and established CV disease. The generalizability of this finding to lower risk population is unknown. We propose to compare cardiovascular outcomes in a more heterogeneous population of T2DM patients treated with SGLT2 inhibitors vs other antidiabetic agents.



3 votes
Idea No. 619